In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Keros Therapeutics Inc (NASDAQ: KROS) was $13.36 for the day, down -7.29% from the previous closing price of $14.41. In other words, the price has decreased by -$7.29 from its previous closing price. On the day, 0.71 million shares were traded. KROS stock price reached its highest trading level at $14.16 during the session, while it also had its lowest trading level at $13.1282.
Ratios:
Our analysis of KROS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.22. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 09 ’25 when ADAR1 Capital Management, LLC bought 934,258 shares for $10.13 per share. The transaction valued at 9,464,512 led to the insider holds 4,392,737 shares of the business.
GORDON CARL L sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 250,000 shares for $44.01 each. As a result, the insider received 11,002,500 and left with 119,522 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 585268160 and an Enterprise Value of -116859888. As of this moment, Keros’s Price-to-Earnings (P/E) ratio for their current fiscal year is 42.64. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 13.62. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.33 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at -0.544 whereas that against EBITDA is 12.964.
Stock Price History:
The Beta on a monthly basis for KROS is 1.06, which has changed by -0.70559716 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is -5.07%, while the 200-Day Moving Average is calculated to be -40.09%.
Shares Statistics:
KROS traded an average of 572.05K shares per day over the past three months and 373790 shares per day over the past ten days. A total of 40.62M shares are outstanding, with a floating share count of 33.72M. Insiders hold about 16.99% of the company’s shares, while institutions hold 89.56% stake in the company. Shares short for KROS as of 1752537600 were 5049215 with a Short Ratio of 8.83, compared to 1749772800 on 4702282. Therefore, it implies a Short% of Shares Outstanding of 5049215 and a Short% of Float of 19.479999.
Earnings Estimates
The current rating of Keros Therapeutics Inc (KROS) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.95, with high estimates of -$0.78 and low estimates of -$1.05.
Analysts are recommending an EPS of between $1.25 and $0.82 for the fiscal current year, implying an average EPS of $1.03. EPS for the following year is -$4.11, with 7.0 analysts recommending between -$2.46 and -$6.07.
Revenue Estimates
A total of 2 analysts have provided revenue estimates for KROS’s current fiscal year. The highest revenue estimate was $249.4M, while the lowest revenue estimate was $229.41M, resulting in an average revenue estimate of $239.41M. In the same quarter a year ago, actual revenue was $3.55M
